A carregar...
OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825
BACKGROUND: Myelotoxicity is a rare but serious side effect of TMZ. In RTOG0825, 16% and 23% of patients experienced grade 3 or higher myelotoxicity during chemoradiation or adjuvant phase, respectively. Our goal was to evaluate risk and validate prediction of myelotoxicity in patients treated with...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5463630/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.033 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|